Effectiveness of Siddha formulations for Sars CoV2 variants infection at home isolation in Chennai, Tamilnadu - A case series

Authors

  • Chitra S. M.
  • Mallika P.
  • Anbu N.

DOI:

https://doi.org/10.51248/.v42i5.1677

Keywords:

Sars CoV 2, variants, Siddha medicines, maha vasantha kusumakaram tablet, RTPCR

Abstract

As Sars CoV 2 infection was accountable for present global pandemic, many novel therapies and traditional medicines have been implied by various countries for the management and prevention of the spread. From the beginning, Corona virus mutation is also progressing with different variants. Delta variant was the most dreadful and contagious one, among the variants, which hospitalized more people. Now, Omicron is the new variant of concern announced by WHO in November 2021 which makes the disease more transmissible. In India, as the cases started rising from January 2022 by this new variant, various measures had been taken for the management of the disease. Traditional Siddha formulations were given for cases reported with positive Covid 19 infection, in home setting, at Chennai and the reports were shared here. Despite, genome sequencing is the precise diagnostic tool for variants detection, the cases reported here were in close possibility of omicron and mixed variants.  Maha vasantha kusumakaram tablet a shastric higher order metallic preparation was proven to be effective with herbal preparations Thippili rasayanam, adathodai kudineer and Amukkara choornam.  The patients recovered in a short span of time and the repeat Real time polymerase chain reaction (RTPCR) tested negative within 10 days. This was highly encouraging that Siddha medicines were proven to be effective in different variants of mutated Covid virus with no adverse effects and the medicines proved to be safe and effective by post- test of liver and renal parameters.  

Author Biographies

Chitra S. M.

Department of PG Maruthuvam, Government Siddha Medical College, Arumbakkam, Chennai, 106, Tamil Nadu, India

Mallika P.

Aringnar Anna Government Hospital of Indian Medicine, Arumbakkam, Chennai, 106, Tamil Nadu, India

 

Anbu N.

Department of PG Maruthuvam, Government Siddha Medical College, Arumbakkam, Chennai, 106, Tamil Nadu, India

References

Banerjee, S. COVID 19: Variants of concern and Variants of Interest. July 13, 2021; https//www.thehindu.com > Sci- Tech > Health.

Delta variant: What we know about the science/CDC https//www.cdc.gov>variants > del

Omicron variant: what u need to know CDC. 2 Feb 2022, https//www.cdc.gov> 2019 ncov > variants > omoicron.

Omicron May Fuel Surges, WHO Warns Amid Transmission Concern, November 29, 2021 By Loni Prinsloo and Jason Gale. https//www.bloomberg.com

How are Omicron cases detected in India? A virologist explains

https://www.thenewsminute.com › News How is Omicron detected? What is S-gene dropout? All you need to know 2022; https//www.hindustantimes.com > India news >

Coronavirus updates | January 6, 2022, The Hindu Bureau.

The Siddha Formulary of India, Department of Health and Family Welfare, Government of India, pg no 129-131.

Mudaliar, K.K.N., Uththamarayan, K.S., Siddha Vaithiya Thirattu, 2014 Edition, Indian Medicine and Homeopathy Department, pp 40, 213,294.

Mudaliar, K.K.N, Siddha maruthuvam pothu, 2016 edition, Indian Medicine and Homeopathy Department, pp.64-65.

Shanmugavelu, M. Noi naadal noi mudal naadal thirattu, Part 2, 1988 edition, Indian Medicine and Homeopathy Department, P 15.

Repurposing Siddha medicine Amukkara choornam as atherapeutic approach for the management of Covid 19: A review, 2021, Ministry of Ayush, Government of India.

Vaniswari, D.S., Arunachalam, K. Anti-inflammatory and antiseptic activity of ancient traditional Siddha drug thippili rasayanam in paediatric care. International Journal of Advanced Research. 2019 May;1035-1039. DOI: https://doi.org/10.21474/IJAR01/9132

Manoharan, A., Chittibabu, C.V., Mubarak, H. Novel action of Thippili rasayanam – Siddha drug against respiratory pathogens. International Journal of Recent Scientific Research. 2016 May; 7(5):10842-10845.

Saraswathi, N.P. K., Thiruthani, M. Drug research on polyherbal Siddha drug Thippili rasayanam. European Journal of Pharmaceutical and Medical Research. 2020; 7(6): 508-514.

Hossain, T., Hoq, O. Therapeutic use of Adathoda vasica. Asian Journal of Medical and Biological Research. 2016 June; 2(2): 156-163. DOI: https://doi.org/10.3329/ajmbr.v2i2.29005

Chitra, S.M., Mallika, P., Anbu, N., Narayanababu, R., Sugunabai, A., David Paul Raj, R.S., et al., An open clinical evaluation of selected siddha regimen in expediting the management of COVID-19 -a randomized controlled study. Journal of Ayurveda Integrative Medicine. 2022 Jan-Mar;13(1):100397. DOI: https://doi.org/10.1016/j.jaim.2021.01.002

Shiva, S., Mari, S., Amuthan, A., Shanmugam, R. Repurposing Siddha mercurial drug for mild to moderate COVID-19 – Case series and exploration of its chemical profile. Journal of Ayurveda and Integrative Medicine. 2022; 13(2):100469. DOI: https://doi.org/10.1016/j.jaim.2021.06.009

Riyasdeen, A., Periasamy, V.S., Paul, P., Alshatwi, A.A., Akbarsha, M.A. Chloroform Extract of Rasagenthi Mezhugu, a Siddha Formulation, as an Evidence-Based Complementary and Alternative Medicine for HPV-Positive Cervical Cancers. Evidence-Based Complementary and Alternative Medicine. 2012; Article ID 136527. 10 pages. https://doi.org/10.1155/2012/136527 DOI: https://doi.org/10.1155/2012/136527

Shajahan, S., Brundha, V. Evaluation of chemical composition of vaalai rasa chendooram: a gold based herbomineral Siddha drug. International Journal of Pharmacology and Clinical Science. 2013; 2(3): 61-66.

Downloads

Published

2022-11-14

How to Cite

1.
S. M. C, P. M, N. A. Effectiveness of Siddha formulations for Sars CoV2 variants infection at home isolation in Chennai, Tamilnadu - A case series. Biomedicine [Internet]. 2022 Nov. 14 [cited 2022 Nov. 27];42(5):1103-9. Available from: https://biomedicineonline.org/home/article/view/1677

Plum Analytics